Activation‐induced cell death: The controversial role of Fas and Fas ligand in immune privilege and tumour counterattack

Immunology and Cell Biology - Tập 80 Số 2 - Trang 131-137 - 2002
Stephen G. Maher1, Deirdre Toomey1, Claire Condron1, David Bouchier‐Hayes1
1Department of Surgery, Royal College of Surgeons in Ireland, Education and Research Centre, Beaumont Hospital, Dublin, Ireland.

Tóm tắt

Activation‐induced cell death (AICD) is the process by which cells undergo apoptosis in a controlled manner through the interaction of a death factor and its receptor. Programmed cell death can be induced by a number of physiological and pathological factors including Fas (CD95)–Fas ligand (FasL/CD95L) interaction, tumour necrosis factor (TNF), ceramide, and reactive oxygen species (ROS). Fas is a 48‐kDa type I transmembrane protein that belongs to the TNF/nerve growth factor receptor superfamily. FasL is a 40‐kDa type II transmembrane protein that belongs to the TNF superfamily. The interaction of Fas with FasL results in a series of signal transductions which initiate apoptosis. The induction of apoptosis in this manner is termed AICD. Activation‐induced cell death and Fas–FasL interactions have been shown to play significant roles in immune system homeostasis. In this review the involvement of Fas and Fas ligand in cell death, with particular reference to the T cell, and the mechanism(s) by which they induce cell death is described. The role of AICD in immune system homeostasis and the controversy surrounding the role of FasL in immune privilege, inflammation, and so‐called tumour counterattack is also discussed.

Từ khóa


Tài liệu tham khảo

10.1073/pnas.95.11.6169

10.1016/S0092-8674(00)81874-7

10.1016/S0041-1345(96)00433-2

10.1084/jem.181.1.71

10.1182/blood.V92.11.4212

Suda T, 1995, Expression of the Fas ligand in cells of T cell lineage, J. Immunol., 22, 3806, 10.4049/jimmunol.154.8.3806

10.1016/0092-8674(91)90614-5

10.3109/10428199809057607

10.1074/jbc.271.22.12687

10.1002/j.1460-2075.1995.tb07096.x

10.1126/science.7510905

10.1016/0167-5699(95)80079-4

10.1126/science.270.5239.1189

10.1038/nm1296-1361

10.1002/jlb.67.1.46

Niehans GA, 1997, Human lung carcinomas express Fas ligand, Cancer Res., 57, 1007

10.1093/emboj/17.6.1675

10.1016/S0014-5793(98)00061-1

10.1093/emboj/17.6.1675

10.1161/01.CIR.99.22.2934

10.1038/76868

10.1038/334395a0

10.1038/329512a0

Mueller DL, 1995, Clinical Immunology: Principles and Practice, 231

Mueller DL, 1987, An accessory cell‐derived costimulatory signal acts independently of protein kinase C activation to allow T cell proliferation and prevent the induction of unresponsiveness, J. Immunol., 142, 2617, 10.4049/jimmunol.142.8.2617

10.1073/pnas.84.15.5409

10.1084/jem.165.2.302

10.1038/373444a0

Su X, 1998, Autocrine and paracrine apoptosis are mediated by differential regulation of Fas ligand activity in two distinct Jurkat T cell populations, J. Immunol., 160, 5288, 10.4049/jimmunol.160.11.5288

10.1038/353858a0

10.1046/j.1440-1711.1999.00818.x

10.1016/S1074-7613(00)80566-X

10.1007/978-1-4615-5357-1_28

Prescott LM, 1996, Microbiology, G1

10.1038/74955

10.1038/85395

10.4049/jimmunol.158.10.4521

10.1038/377630a0

10.1084/jem.159.1.1

10.4049/jimmunol.164.10.5023

Mountz J, 1985, Oncogene expression in autoimmune mice, J. Mol. Cell Immunol., 2, 121

10.1073/pnas.94.8.3943

10.1097/00007890-200005150-00043

10.1007/BF02256600

10.4049/jimmunol.165.10.5480

10.1038/85357

10.7326/0003-4819-130-7-199904060-00020

10.1076/0271-3683(200001)2011-HFT054

10.1136/bjo.84.10.1130

10.1084/jem.184.3.1075

10.1073/pnas.94.12.6420

10.1007/s004320000181

10.4049/jimmunol.160.11.5669

10.1136/gut.44.2.156

Okada K, 2000, Frequency of apoptosis of tumor‐infiltrating lymphocytes induced by Fas counterattack in human colorectal carcinoma and its correlation with prognosis, Clin. Cancer Res., 6, 3560

Shibakita M, 1999, Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer, Clin. Cancer Res., 5, 2464

10.1016/S0002-9440(10)61772-5

Smith D, 1998, Technical note: Aberrant detection of cell surface Fas ligand with anti‐peptide antibodies, J. Immunol., 160, 4159, 10.4049/jimmunol.160.9.4159

10.1126/science.275.5302.960

Zipp F, 1997, Human autoreactive and foreign antigen‐specific T cells resist apoptosis induced by soluble recombinant CD95 ligand, J. Immunol., 159, 2108, 10.4049/jimmunol.159.5.2108

Berthou C, 1997, Acquisition of granzyme B and Fas ligand proteins by human keratinocytes contributes to epidermal cell defence, J. Immunol., 159, 5293, 10.4049/jimmunol.159.11.5293

Lee JW, 1997, HLA‐DR‐Triggered inhibition of haemopoiesis involves Fas/Fas ligand interactions and is prevented by c‐kit ligand, J. Immunol., 159, 3211, 10.4049/jimmunol.159.7.3211

10.1084/jem.185.8.1511

Kiener PA, 1997, Human monocytic cells contain high levels of intracellular Fas ligand, J. Immunol., 159, 1594, 10.4049/jimmunol.159.4.1594

10.1016/S0022-1759(98)00100-8

Zaks T, 1999, Fas‐mediated suicide of tumor‐reactive T cells following activation by specific tumor: Selective rescue by caspase inhibition, J. Immunol., 162, 3273, 10.4049/jimmunol.162.6.3273

Chappell D, 1999, Human melanoma cells do not express Fas (Apo‐1/CD95) ligand, Cancer Res., 59, 59

10.1073/pnas.94.25.13862

10.1126/science.274.5291.1363

10.1126/science.279.5359.2015a

10.1126/science.279.5359.2015a

10.1038/sj.cdd.4400813

10.1002/1521-4141(200108)31:8<2504::AID-IMMU2504>3.0.CO;2-C

10.1084/jem.191.7.1209

10.1126/science.282.5394.1714

10.1016/S0092-8674(00)81266-0

Thông tin
Thông tin xuất bản

Immunology and Cell Biology

Tập 80 Số 2

131-137

Thông tin tác giả